FUSION ANTIBODIES PLC
Get an alert when FUSION ANTIBODIES PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£1k
+190.5% vs 2025
Net assets
£1.6k
+114.6% vs 2025
Employees
24
+14.3% vs 2025
Profit before tax
-£1.1k
+29.3% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
As stated in Note 2, these events or conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.
-
Audit opinion: Qualified
Latest auditor's report carried a non-clean opinion.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2026-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £1,136,000 | £1,965 | £2,110 | +7.4% | |
| Operating profit | -£2,288,000 | -£1,628 | -£1,133 | +30.4% | |
| Profit before tax | -£2,289,000 | -£1,626 | -£1,149 | +29.3% | |
| Net profit | -£2,226,000 | — | -£1,149 | — | |
| Cash | £1,199,000 | £359 | £1,043 | +190.5% | |
| Total assets less current liabilities | — | £787 | £1,884 | +139.4% | |
| Net assets | £1,793,000 | — | £1,622 | — | |
| Equity | £1,793,000 | £756 | £1,622 | +114.6% | |
| Average employees | 31 | 21 | 24 | +14.3% | |
| Wages | £1,191,000 | £1,032 | £1,112 | +7.8% | |
| Directors' remuneration | £349,000 | £421 | £524 | +24.5% | |
| Directors' pension contributions | £18,000 | £20 | £21 | +5% | |
| Highest paid director | £169,000 | £207 | £258 | +24.6% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Operating margin | — | -82.8% | -53.7% | |
| Net margin | -196.0% | — | -54.5% | |
| Return on capital employed | — | -206.9% | -60.1% | |
| Gearing (liabilities / total assets) | 25.9% | — | 40.5% | |
| Current ratio | 3.87x | 2.16x | 3.20x | |
| Interest cover | — | — | -56.65x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- FUSION ANTIBODIES PLC 2017-12-11 → present
- FUSION ANTIBODIES LIMITED 2000-11-29 → 2017-12-11
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- Price Bailey LLP
- Audit opinion
- Qualified
- Going concern
- Material uncertainty disclosed
“As stated in Note 2, these events or conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.”
Significant events
- “On 30 March 2026, the Company announced that it had entered into an agreement to transfer the ownership of certain background IP owned by Fusion to Finn Therapeutics for a consideration of £250,000.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SMYTH, Stephen Barry | Secretary | 2023-09-16 | — | — |
| BAKER, Matthew Paul | Director | 2022-03-01 | Sep 1970 | British |
| BUICK, Richard, Dr | Director | 2011-08-15 | Aug 1976 | British |
| DOUGLAS, Simon Gordon, Dr | Director | 2006-09-07 | Oct 1958 | British |
| KINKAID, Adrian Robert, Dr | Director | 2022-08-25 | Mar 1967 | British |
| SMYTH, Stephen Barry | Director | 2023-09-13 | Oct 1974 | British |
| WALSH, Colin James | Director | 2007-07-03 | Aug 1955 | Irish |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| FAIR, James Alexander | Secretary | 2017-10-13 | 2023-05-31 |
| JOHNSTON, Frances | Secretary | 2023-05-31 | 2023-07-28 |
| MOORE, William David John | Secretary | 2000-11-29 | 2008-12-04 |
| TUGLAW SECRETARIAL LIMITED | Corporate Secretary | 2008-12-04 | 2017-10-13 |
| BRITTAIN-DISSONT, Tristan | Director | 2008-08-01 | 2009-01-28 |
| CADOGAN, John Ivan George, Sir | Director | 2005-03-02 | 2017-12-11 |
| COURTENAY-LUCK, Nigel Stephen, Prof | Director | 2009-01-16 | 2014-06-13 |
| FAIR, James Alexander | Director | 2017-08-01 | 2023-05-31 |
| FERGUSON, Sonya Maria | Director | 2016-06-10 | 2023-10-26 |
| JOHNSTON, James Anthony, Prof | Director | 2000-11-29 | 2011-09-01 |
| JONES, Richard Anthony | Director | 2021-02-16 | 2022-03-11 |
| KERR, Paul Gerard, Dr | Director | 2011-09-01 | 2021-02-16 |
| MAWSON, Alan, Dr | Director | 2004-10-22 | 2022-03-31 |
| MAYNARD, John Charles, Dr | Director | 2006-01-31 | 2011-09-01 |
| MOORE, William David John | Director | 2004-05-26 | 2017-12-11 |
| TOWNSLEY, Michael Colin | Director | 2000-11-29 | 2006-09-07 |
| WATTS, Timothy William | Director | 2017-12-18 | 2022-09-23 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 222 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-10-29 RESOLUTIONS Resolution
- 2025-04-14 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-29 | AA | accounts | Accounts with accounts type full | |
| 2026-02-11 | SH01 | capital | Capital allotment shares | |
| 2026-02-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-29 | RESOLUTIONS | resolution | Resolution | |
| 2025-10-15 | AUD | auditors | Auditors resignation company | |
| 2025-09-10 | AA | accounts | Accounts with accounts type full | |
| 2025-09-04 | SH01 | capital | Capital allotment shares | |
| 2025-04-14 | RESOLUTIONS | resolution | Resolution | |
| 2025-04-11 | SH01 | capital | Capital allotment shares | |
| 2025-03-25 | SH01 | capital | Capital allotment shares | |
| 2025-01-20 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-01-06 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-09-17 | AA | accounts | Accounts with accounts type full | |
| 2024-03-11 | SH01 | capital | Capital allotment shares | |
| 2024-03-08 | SH01 | capital | Capital allotment shares | |
| 2023-12-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-18 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-10 | AA | accounts | Accounts with accounts type full | |
| 2023-09-28 | AP03 | officers | Appoint person secretary company with name date | |
| 2023-09-26 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.